<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741647</url>
  </required_header>
  <id_info>
    <org_study_id>ZU-IRB #:4791/30-7-2018</org_study_id>
    <nct_id>NCT03741647</nct_id>
  </id_info>
  <brief_title>Sleep Apnea and Lung Cancer</brief_title>
  <official_title>Prognostic Significance of Sleep Apnea in Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      cases of locally advanced non small cell lung cancer (diagnosed by PET/CT scan and
      histopathological confirmation) will be screened for sleep disorders by Epworth sleepiness
      scale then confirmed by full night polysomnographic study. Blood sample to detect some
      genetic determinants will be withdrawn
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>assessment Response to treatment</measure>
    <time_frame>6 weeks from ending therapy</time_frame>
    <description>CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>confirmed Response to treatment</measure>
    <time_frame>4 weeks from assessment response</time_frame>
    <description>CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 months from confirmed response to treatment</time_frame>
    <description>CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months from confirmed response to treatment</time_frame>
    <description>CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>9 months from confirmed response to treatment</time_frame>
    <description>CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 months from confirmed response to treatment</time_frame>
    <description>CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>regular patient follow up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months after enrollment</time_frame>
    <description>regular patient follow up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>9 months after enrollment</time_frame>
    <description>regular patient follow up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months after enrollment</time_frame>
    <description>regular patient follow up visit</description>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Locally Advanced Non Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>sleep study and blood sample</intervention_name>
    <description>full night polysomnographic study and blood sample to detect some genetic issues</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        - patients with locally advanced non small cell lung cancer diagnosed, managed and followed
        up in clinical oncology department, zagazig university hospitals
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with locally advanced non small cell lung cancer

        Exclusion Criteria:

          -  unable or refuse to perform sleep study

          -  metastatic cases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ahmad Abbas</name>
      <address>
        <city>Zagazig</city>
        <state>Asharqia</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Ahmad Abbas</investigator_full_name>
    <investigator_title>Principal investigator &amp;lecturer of chest disases zagazig university</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

